LY4584180 / Eli Lilly - LARVOL DELTA

LY4584180, a novel BCL6 molecular glue, demonstrates antitumor efficacy in preclinical models of B Cell NHL (AACR 2026) - P1 | "Int J Mol Sci 2024, 25:10968 3Groocock L, et al. Blood 2024; 144 (Supplement 1): 957"

Preclinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL6 • CRBN

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers (clinicaltrials.gov) - P1 | N=360 | Not yet recruiting | Sponsor: Eli Lilly and Company

First-in-human • New P1 trial • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology